Clinical trial · Observational
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body. Women on aromatase inhibitors appear to experience joint pains and arthralgia. The aim of this study is to determine whether the joint pains experienced by some women on aromatase inhibitors is associated with more defects in their cartilage, compared to women not receiving this therapy. Using the magnetic resonance imaging (MRI) technique, the knee joint will be examined to assess changes in cartilage volume over time.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arthralgia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aromatase inhibitors (letrozole, anastrozole) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Knee Cartilage Volume
- timeFrame
- Baseline, two years
- description
- change in medial and lateral articular tibial cartilage volume over two years
Secondary outcomes (1)
- measure
- Knee Subchondral Bone Expansion
- timeFrame
- Baseline, Two years
- description
- change in subchondral bone expansion area over two years
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: Group 1 : * Aged 40 - 65 * Non-hysterectomised women who have undergone breast surgery * Women on aromatase inhibitors within preceding 12 weeks Group 2 : control group * Healthy, non-hysterectomised women aged 40-65 . Exclusion Criteria: * Previous knee injury requiring non-weight bearing treatment for \> 24 hrs or surgery (including arthroscopy) * Inability to complete the study (eg proposed relocation) * Contraindication to undergoing an MRI including pacemaker, metal sutures, presence of shrapnel, iron filings in eye * Claustrophobia Additional Exclusions for Group 1 * Treatment with tamoxifen for \> 8 weeks prior to commencement * Knee pain lasting for \>24 hours in the last 5 years (prior to commencement on anastrozole or letrozole) * Anastrazole or Letrozole therapy for \> 12 weeks
References
Publications (0)
Data not yet available